Search results for " DIABETES MELLITUS"

showing 10 items of 309 documents

A Decision Support Tool for Appropriate Glucose-Lowering Therapy in Patients with Type 2 Diabetes

2015

Contains fulltext : 152084.pdf (Publisher’s version ) (Open Access) BACKGROUND: Optimal glucose-lowering therapy in type 2 diabetes mellitus requires a patient-specific approach. Although a good framework, current guidelines are insufficiently detailed to address the different phenotypes and individual needs of patients seen in daily practice. We developed a patient-specific decision support tool based on a systematic analysis of expert opinion. MATERIALS AND METHODS: Based on the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) 2012 position statement, a panel of 12 European experts rated the appropriateness (RAND/UCLA Appropriateness Method) of tre…

medicine.medical_specialtyDecision support systemEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]MEDLINEType 2 diabetesComorbidityHypoglycemiaGlucagon-Like Peptide-1 ReceptorBody Mass IndexEndocrinologyLife ExpectancyClinical ProtocolsInternal medicineHealth careReceptors GlucagonMedicineHumansHypoglycemic AgentsInsulinPrecision MedicineIntensive care medicineExpert TestimonyReimbursementComputingMilieux_MISCELLANEOUSGlycated HemoglobinDipeptidyl-Peptidase IV InhibitorsPioglitazonebusiness.industryDrug SubstitutionType 2 Diabetes MellitusMetabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6]Original ArticlesPrecision medicinemedicine.diseaseDecision Support Systems ClinicalHypoglycemiaMetformin3. Good healthEuropeMedical Laboratory TechnologyEndocrinologySulfonylurea CompoundsDiabetes Mellitus Type 2Drug Therapy CombinationThiazolidinedionesbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance

2007

Type 2 diabetes is characterized by cellular and extracellular Mg depletion. Epidemiologic studies showed a high prevalence of hypomagnesaemia and lower intracellular Mg concentrations in diabetic subjects. Insulin and glucose are important regulators of Mg metabolism. Intracellular Mg plays a key role in regulating insulin action, insulin-mediated-glucose uptake and vascular tone. Reduced intracellular Mg concentrations result in a defective tyrosine-kinase activity, post-receptorial impairment in insulin action, and worsening of insulin resistance in diabetic patients. Mg deficit has been proposed as a possible underlying common mechanism of the "insulin resistance" of different metabolic…

medicine.medical_specialtyDiabetes riskmedicine.medical_treatmentBiophysicsType 2 diabetesBiochemistryInsulin resistanceDiabetes mellitusInternal medicineHumansInsulinMedicineMagnesiumMolecular BiologyMetabolic Syndromebusiness.industryInsulinType 2 Diabetes Mellitusmedicine.diseaseGlucoseEndocrinologyDiabetes Mellitus Type 2Insulin ResistanceMetabolic syndromebusinessIntracellularArchives of Biochemistry and Biophysics
researchProduct

Models for non-alcoholic fatty liver disease: a link with vascular risk.

2008

Non alcoholic fatty liver disease (NAFLD) is often part of the metabolic syndrome which includes central obesity, dyslipidaemia, insulin resistance/type 2 diabetes mellitus and hypertension. In turn, NAFLD may be associated with an increased vascular risk. Several experimental models which express histological steatosis or steatohepatitis with fibrosis have been described. This review identifies those models of NAFLD with features of vascular risk.

medicine.medical_specialtyDiseasedigestive systemGastroenterologyInsulin resistanceNAFLD central obesity dyslipidaemia insulin resistance/type 2Risk FactorsInternal medicineDrug DiscoveryAnimalsHumansMedicineVascular DiseasesRisk factorPharmacologybusiness.industryFatty livernutritional and metabolic diseasesType 2 Diabetes Mellitusmedicine.diseasedigestive system diseasesFatty LiverDisease Models AnimalEndocrinologyInflammation MediatorsSteatosisMetabolic syndromeSteatohepatitisbusiness
researchProduct

Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance in primary care.

2019

Chronic kidney disease (CKD) is one of the most common complications of type 2 diabetes mellitus (T2DM). Furthermore, CKD confers a considerable increase in the risk of cardiovascular (CV) morbidity and mortality. In line with the need to improve knowledge in this field, this article aims to describe the renal endpoints used in the different cardiovascular outcome trials (CVOTs). The objective is to better know the renal variables used in the different CVOTs in order to optimize the implementation of advances in the prevention of progressive diabetic kidney disease in patients with T2DM in clinical practice.

medicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismDiseasePrimary careType 2 diabetesurologic and male genital diseasesGlobal HealthDiabetic nephropathy03 medical and health sciences0302 clinical medicineRisk FactorsDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsDiabetic Nephropathies030212 general & internal medicineIntensive care medicineNutrition and DieteticsPrimary Health Carebusiness.industryType 2 Diabetes Mellitusmedicine.diseaseClinical trialSurvival RateDiabetes Mellitus Type 2Cardiovascular DiseasesMorbidityFamily PracticebusinessKidney diseasePrimary care diabetes
researchProduct

Clinical inertia is the enemy of therapeutic success in the management of diabetes and its complications: A narrative literature review

2020

AbstractDiabetes mellitus is a chronic disease characterized by high social, economic and health burden, mostly due to the high incidence and morbidity of diabetes complications. Numerous studies have shown that optimizing metabolic control may reduce the risk of micro and macrovascular complications related to the disease, and the algorithms suggest that an appropriate and timely step of care intensification should be proposed after 3 months from the failure to achieve metabolic goals. Nonetheless, many population studies show that glycemic control in diabetic patients is often inadequate. The phenomenon of clinical inertia in diabetology, defined as the failure to start a therapy or its i…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismPopulationTherapeutic inertiaDiseaseReviewDiabetes mellitusEpidemiologyType 2 diabetes mellitusInternal MedicinemedicineIntensive care medicineeducationlcsh:RC620-627Therapeutic inertiaGlycemiceducation.field_of_studyClinical inertia Diabetes care Italian association of medical diabetologists Therapeutic inertia Type 2 diabetes mellitusbusiness.industryType 2 Diabetes Mellitusmedicine.diseaselcsh:Nutritional diseases. Deficiency diseasesClinical inertiaMetabolic control analysisItalian association of medical diabetologistsbusinessDiabetes care
researchProduct

Type 2 diabetes mellitus and osteoarthritis

2019

Objectives: Type 2 diabetes mellitus (T2DM) and osteoarthritis (OA) are common diseases that frequently co-exist, along with overweight/obesity. While the mechanical impact of excess body weight on joints may explain lower limb OA, we sought to explore whether T2DM is linked to OA outside of excess weight and whether T2DM may play a role in OA pathophysiology. The consequence of T2DM on OA outcomes is a question of research interest. Methods: We conducted a critical review of the literature to explore the association between T2DM and OA, whether any association is site-specific for OA, and whether the presence of T2DM impacts on OA outcomes. We also reviewed the literature to assess the saf…

medicine.medical_specialtyEvidence-based practicetype 2 diabetes mellituendocrine system diseasesMedicinaOsteoarthritisOverweightPathophysiologyArticle03 medical and health sciences0302 clinical medicineInsulin resistanceRheumatologyInternal medicineOsteoarthritisType 2 diabetes mellitusMedicineHumans030212 general & internal medicineObesityRisk factor030203 arthritis & rheumatologyddc:616[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism[SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systembusiness.industryType 2 Diabetes Mellitusnutritional and metabolic diseases[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismmedicine.diseaseObesity3. Good healthInstitutional repositoryAnesthesiology and Pain MedicineDiabetes Mellitus Type 2[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemDisease Progressionosteoarthritimedicine.symptomInsulin ResistanceSafetybusiness
researchProduct

Development of a fuzzy expert system for the control of glycemia in type 1 diabetic patients

2011

Abstract The paper describes the structure and the characteristics of an expert system that allows the optimization of postprandial glycemia in type 1 diabetic patients. The expert system is able to provide patients with the number of rapid insulin units that must be taken in order to keep the blood glucose level close to the omeostatic condition in the hours following a meal.

medicine.medical_specialtyFuzzy logic systemSettore ING-IND/26 - Teoria Dello Sviluppo Dei Processi ChimiciFuzzy expert systembusiness.industryInsulinmedicine.medical_treatmentControl (management)computer.software_genremedicine.diseaseExpert systemEndocrinologyPostprandialInternal medicineDiabetes mellitusEmergency medicinemedicinebusinesscomputerfuzzy logic system neuro fuzzy system expert system diabetes mellitus glycemia control
researchProduct

Gelatinases and their tissue inhibitors in metabolic syndrome

2014

medicine.medical_specialtyGelatinasesEndocrinologySettore MED/09 - Medicina Internabusiness.industryInternal medicinemedicineMetabolic syndromeCardiology and Cardiovascular Medicinebusinessmedicine.diseaseMetalloproteinase Diabetes mellitus
researchProduct

HLA antigens and immunoresponsiveness to insulin in insulin-dependent diabetes mellitus.

2008

HLA-A and B antigens were determined in 112 patient with insulin-dependent juvenile onset diabetes mellitus, who could be subdivided into “non” and “high responders” to insulin. The data revealed a trend of an association of these diabetes subgroups with only one of the diabetes-associated antigens HLA-B8 and HLA-BW15 and indicated the existence of at least two different genetic constellations for susceptibility to juvenile diabetes mellitus. One form with a strong immune-response to insulin seemed to be associated with HLA-BW 15 and the other form without humoral immunoreactivity to insulin seemed to be associated with the presence of HLA-B8 and the absence of HLA-B7.

medicine.medical_specialtyHigh respondermedicine.medical_treatmentInsulin AntibodiesImmunologyHuman leukocyte antigenBiochemistryAntigenHLA AntigensDiabetes mellitusInternal medicineHistocompatibility AntigensGeneticsmedicineDiabetes MellitusImmunology and AllergyHumansInsulinbusiness.industryInsulinGeneral Medicinemedicine.diseaseEndocrinologyInsulin dependent diabetesImmunologyJuvenile diabetes mellitusbusinessJuvenile-onset diabetes mellitusTissue antigens
researchProduct

Steatohepatitis and type 2 diabetes mellitus are influenced by genetic susceptibility to increased intestinal permeability in patients with non-alcoh…

2017

medicine.medical_specialtyIntestinal permeabilityHepatologybusiness.industrySettore MED/12 - GASTROENTEROLOGIAFatty liverGastroenterologyType 2 Diabetes MellitusNon alcoholicDiseasemedicine.diseaseGastroenterologyN/AInternal medicinemedicineGenetic predispositionIn patientSteatohepatitisbusinessDigestive and Liver Disease
researchProduct